the aid library

Pathophysiology of the human immunodeficiency virus

N. R. Calles; D. Evans; D.L. Terlonge Baylor International Pediatric AIDS Initiative (BIPAI) (2019) C2

Accessed: 03.09.2019

Immunological Interactions of Tuberculosis with Drugs and Substance Use: A Systematic Review and Update

N. G. Kiobi, S. N. Nebere, J. K. Karanja (2016) CC

Journal of Pulmonary & Respiratory Medicine 6: 326. doi:10.4172/2161-105X.1000326

HIV and young people who inject drugs

A. Armstrong; J. Baer; R. Baggaley; et al. UNAIDS; World Health Organization; UNFPA; et al. (2015) C_WHO

Technical Brief

Efficacy and Safety of Pafuramidine versus Pentamidine Maleate for Treatment of First Stage Sleeping Sickness in a Randomized, Comparator-Controlled, International Phase 3 Clinical Trial

Pohlig G, Bernhard SC, Blum J, Burri C, Mpanya A, PLOS Neclected Tropical Diseases (2016) CC

This was a Phase 3, multi-center, randomized, open-label, parallel-group, active control study where 273 male and female patients with first stage Trypanosoma brucei gambiense HAT were treated at six sites: one trypanosomiasis reference center in Angola, one hospital in South Sudan, and four hospita ... more

Anaesthesia equipment for resource-poor environments

B. A. McCormick and R. J. Eltringham (2007) CC

The design of anaesthesia equipment for use in hospitals in the developing world must take intoaccount the local conditions, particularly whether reliable supplies of compressed oxygen andelectricity are available. Designs should ensure that maintenance is feasible locally. Internationalstandards sh ... more

Transmission modelling of environmentally persistent zoonotic diseases: a systematic review

Rees, E.M.; A. Minter, J. Edmunds et al. The Lancet (2021) CC

The Lancet Planetary Health Volume 5, ISSUE 7, e466-e478, July 01, 2021 Transmission of many infectious diseases depends on interactions between humans, animals, and the environment. Incorporating these complex processes in transmission dynamic models can help inform policy and disease control int ... more

Public perceptions of intellectual disability in a shantytown community in Lima, Peru

M.S. O’Shea, J. M.Girón, L. Cabrera, et al. (2012) CC

Int Health. 2012 December 1; 4(4): 253–259. doi:10.1016/j.inhe.2012.07.001

Financing HIV Programming: How Much Should Low And Middle-Income Countries and their Donors Pay?

Galarraga, O.; V. J. Wirtz; Y. Santa-Ana-Tellez et al. PLOS One (2013) C1

Global HIV control funding falls short of need. To maximize health outcomes, it is critical that national governments sustain reasonable commitments, and that international donor assistance be distributed according to country needs and funding gaps. We develop a country classification framework in t ... more

A worldwide charter for all children with asthma

Szefler, S. J.; Fitzgerald, D. A.; Adachi, Y.; (2020) CC2

Asthma is the commonest chronic childhood disease and encompasses a spectrum of airway diseases with similar symptoms. Inaccurate diagnosis remains common, especially in younger children, with failure to characterize the different “asthmas.” Children worldwide repeatedly suffer symptoms which se ... more

Take Charge! A Reproductive Health Guide for Women with Disabilities

Healy, K.; Panko Reis, J.; M. Martin Access Living; The Empowered Fe Fes (2016) CC

Mobile Populations

M. Smelyanskaya, J. Duncan (The Focus Group Consulting); C. Daniels, et al. Stop TB Partnership; UNOPS; END TB (2015) C1

Key populations brief.

New Perspectives on Global Health Spending for Universal Health Coverag

Xu K., Soucat A., Kutzin J., et al. World Health Organization (2018) C_WHO

The report summarizes key global health expenditure patterns and trends, and illustrates the potential of the new database to inform thinking about financing reforms to progress towards UHC, and also raises issues for further research. It analyses the following areas:

Mental health and HIV/AIDS: the need for an integrated response

R. H. Remien; M. J. Stirratt; N. Nguyen; et al. AIDS; Wolters Kluwer (2019) CC

Editorial Review AIDS 2019, 33:1411–1420

Early versus late BCG vaccination in HIV-1- exposed infants in Uganda: study protocol for a randomized controlled trial

V. Nankabirwa , J. K. Tumwine, O. Namugga, et al. Trials; BooMed Central (2017) CC

Trials (2017) 18:152, DOI 10.1186/s13063-017-1881-z

Government policy interventions to reduce human antimicrobial use: A systematic review and evidence map

Van Katwyk, S. R.; Grimshaw, J. M.; et al (2019) C2

BACKGROUND: Growing political attention to antimicrobial resistance (AMR) offers a rare opportunity for achieving meaningful action. Many governments have developed national AMR action plans, but most have not yet implemented policy interventions to reduce antimicrobial overuse. A systematic evidenc ... e map can support governments in making evidence-informed decisions about implementing programs to reduce AMR, by identifying, describing, and assessing the full range of evaluated government policy options to reduce antimicrobial use in humans. METHODS AND FINDINGS: Seven databases were searched from inception to January 28, 2019, (MEDLINE, CINAHL, EMBASE, PAIS Index, Cochrane Central Register of Controlled Trials, Web of Science, and PubMed). We identified studies that (1) clearly described a government policy intervention aimed at reducing human antimicrobial use, and (2) applied a quantitative design to measure the impact. We found 69 unique evaluations of government policy interventions carried out across 4 of the 6 WHO regions. These evaluations included randomized controlled trials (n = 4), non-randomized controlled trials (n = 3), controlled before-and-after designs (n = 7), interrupted time series designs (n = 25), uncontrolled before-and-after designs (n = 18), descriptive designs (n = 10), and cohort designs (n = 2). From these we identified 17 unique policy options for governments to reduce the human use of antimicrobials. Many studies evaluated public awareness campaigns (n = 17) and antimicrobial guidelines (n = 13); however, others offered different policy options such as professional regulation, restricted reimbursement, pay for performance, and prescription requirements. Identifying these policies can inform the development of future policies and evaluations in different contexts and health systems. Limitations of our study include the possible omission of unpublished initiatives, and that policies not evaluated with respect to antimicrobial use have not been captured in this review. CONCLUSIONS: To our knowledge this is the first study to provide policy makers with synthesized evidence on specific government policy interventions addressing AMR. In the future, governments should ensure that AMR policy interventions are evaluated using rigorous study designs and that study results are published. more